Inhibitory effect of Sialyl Lewis-X oligosaccharide on reperfusion injury -Optimal timing and temperature during cardioplegia-
唾液酸路易斯-X寡糖对再灌注损伤的抑制作用-心脏停搏时的最佳时机和温度-
基本信息
- 批准号:13671416
- 负责人:
- 金额:$ 2.11万
- 依托单位:
- 依托单位国家:日本
- 项目类别:Grant-in-Aid for Scientific Research (C)
- 财政年份:2001
- 资助国家:日本
- 起止时间:2001 至 2002
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
Objective: Effects of supplemental Sialyl Lewis-X analogue, a major ligand for all three selectin family members, during warm blood cardioplegia were expressed in the blood perfused isolated rat heart.Methods: The isolated hearts were arrested for 60 min with warm blood cardioplegia given at 20-min intervals. This was followed by 60 min of reperfusion. The hearts were divided into the following two groups according to the supplemental drugs added to the cardioplegic solution. The Control group (n=6) received standard warm blood cardioplegia. The SLX group (n=6) received warm blood cardioplegia supplemented with Sialyl Lewis-X analogue (60μg/ml). Cardiac function, endothelial function, myocardial metabolism and myocardial myeroperoxidase activity were assessed before and after cardioplegic arrest.Results: Left ventricular developed pressure and dp/dt were significantly (p<0.05) greater and -dp/dt was significantly (p<0.05) lower in the SLX group than the control group during reperfusion. Coronary flow at 15 min of reperfusion and NO production, when acetylcholine chloride was added were significantly (p<0.05) greater in the SLX group than the control group. Myeloperoxidase activity was significantly (p<0.05) lower in the SLX than the control group.Conclusions: The results suggest that selectin-mediated endothelial-leukocyte interactions may play an important role in myocardial ischemia and reperfusion injury. Supplementation of Sialyl Lewis-X analogue during warm blood cardioplegia may provide superior myocardial protection by suppressing leukocyte-endothelial interaction during early reperfusion period.
目的:补充Sialyl Lewis-X类似物的影响,一个主要的配体为所有三个选择素家族成员,在温血心脏停搏液中表达的血液灌注离体大鼠heart.Methods:离体心脏停搏60分钟,给予温血心脏停搏液在20分钟的时间间隔。然后再灌注60分钟。根据心脏停搏液中添加的补充药物将心脏分为以下两组。对照组(n=6)给予标准温血停搏液。SLX组(n=6)给予含Sialyl Lewis-X类似物(60μg/ml)的温血停搏液。结果:与对照组比较,SLX组再灌注时左室发展压(VP)、dp/dt显著升高(P<0.05),-dp/dt显著降低(P<0.05); SLX组再灌注15分钟时的冠脉流量和NO生成量均显著高于对照组(p<0.05)。SLX组髓过氧化物酶活性显著低于对照组(P<0.05)。结论:选择素介导的内皮细胞-白细胞相互作用在心肌缺血再灌注损伤中可能起重要作用。在温血停搏液中加入唾液酸化Lewis-X类似物可能通过抑制再灌注早期白细胞-内皮细胞相互作用而提供上级心肌保护。
项目成果
期刊论文数量(15)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
N.Hayashida, et l.: "Does Off-pump Coronary Artery Bypass Grafting Really Preserve Renal Function?"Circulation Journal. 66. 921-925 (2002)
N.Hayashida 等人:“非体外循环冠状动脉旁路移植真的能保护肾功能吗?”循环杂志。
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
H.Teshima, et al.: "Obstruction of St.Jude Medical valves in the aortic position : Histology and immunohistrochemistry of pannus"J Thorac Cardiovase Surg. (in press).
H.Teshima 等人:“主动脉位置 St.Jude 医疗瓣膜阻塞:血管翳的组织学和免疫组织化学”J Thorac Cardiovase Surg。
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
N.Hayashida: "Does Off-pump Coronary Artery Bypass Grafting Really Preserve Renal Function?"Circulation Journal. 66. 921-925 (2002)
N.Hayashida:“非体外循环冠状动脉旁路移植真的能保留肾功能吗?”循环杂志。
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
H. Teshima, et al: "Obstruction of St. Jude Medical valves in the aortic position: History and immunohistrochemistry of pannus"J Thorac Surg. in press.
H. Teshima 等人:“主动脉位置 St. Jude 医疗瓣膜阻塞:血管翳的历史和免疫组织化学”J Thorac Surg。
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
H.Teshima, et al.: "Detection of Pannus by Multidetector-Row Computed Tomography"Ann Thorac Surg. 75. 1631-1633 (2003)
H.Teshima 等人:“通过多探测器行计算机断层扫描检测血管翳”Ann Thorac Surg。
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
HAYASHIDA Nobuhiko其他文献
HAYASHIDA Nobuhiko的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('HAYASHIDA Nobuhiko', 18)}}的其他基金
Inhibitory effects of Sialyl Lewis^x oligosaccharide on reperfusion injury by avoidance of apoptosis
Sialyl Lewis^x 寡糖通过避免细胞凋亡对再灌注损伤的抑制作用
- 批准号:
15591505 - 财政年份:2003
- 资助金额:
$ 2.11万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
相似海外基金
A novel treatment for REBOA complications: Hydrogen gas inhalation therapy to alleviate oxidative stress due to ischemia-reperfusion injury
REBOA并发症的新型治疗方法:氢气吸入疗法减轻缺血再灌注损伤引起的氧化应激
- 批准号:
23K21458 - 财政年份:2024
- 资助金额:
$ 2.11万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Development ofsynthetic heparin to protect liver graft from ischemia reperfusion injury duringtransplantation
开发合成肝素以保护移植肝免受移植过程中的缺血再灌注损伤
- 批准号:
10759102 - 财政年份:2023
- 资助金额:
$ 2.11万 - 项目类别:
The Role of Neutrophils in Ischemia/Reperfusion Injury following Acute Stroke
中性粒细胞在急性中风后缺血/再灌注损伤中的作用
- 批准号:
10606952 - 财政年份:2023
- 资助金额:
$ 2.11万 - 项目类别:
Zinc Protection Against Ischemia-Reperfusion Injury in Heart
锌可预防心脏缺血再灌注损伤
- 批准号:
10652915 - 财政年份:2023
- 资助金额:
$ 2.11万 - 项目类别:
Ischemia/Reperfusion injury and Myocardial edema
缺血/再灌注损伤和心肌水肿
- 批准号:
10718260 - 财政年份:2023
- 资助金额:
$ 2.11万 - 项目类别:
Role of Gasdermin D/E in intestinal ischemia-reperfusion injury
Gasdermin D/E 在肠缺血再灌注损伤中的作用
- 批准号:
23K15529 - 财政年份:2023
- 资助金额:
$ 2.11万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Monocytic-MDSCs as resolution mediators of post-transplant lung ischemia-reperfusion injury
单核细胞-MDSC作为移植后肺缺血再灌注损伤的解决介质
- 批准号:
10677290 - 财政年份:2023
- 资助金额:
$ 2.11万 - 项目类别:
Role of Lipid Metabolism in Hepatic Ischemia Reperfusion Injury in Steatotic Livers
脂质代谢在脂肪肝缺血再灌注损伤中的作用
- 批准号:
10664736 - 财政年份:2023
- 资助金额:
$ 2.11万 - 项目类别:
ETS2-dependent control in cardiomyocyte ischemia/reperfusion injury
ETS2 依赖性控制心肌细胞缺血/再灌注损伤
- 批准号:
10501545 - 财政年份:2022
- 资助金额:
$ 2.11万 - 项目类别: